In a study, among TIGIT, lymphocyte-activation gene 3 protein (LAG-3), and CD96, only TIGIT was significantly increased after CAR-T cell therapy relapse in patients with mantle cell lymphoma (MCL) or other non-Hodgkin’s lymphomas, suggesting a central role of TIGIT in inhibiting normal T cell function in terms of MCL [72, 73]. The gene discussed is LAG3; the disease is mantle cell lymphoma.